DMT
SOURCES CITED — 5
Executive Summary
Dimethyltryptamine (DMT) is an endogenous hallucinogenic compound and structural analog of serotonin that induces a brief but intense state of altered consciousness characterized by "entity contact" and the perception of high-dimensional geometries. While categorized as a Schedule I controlled substance in the United States under the Controlled Substances Act of 1970, DMT has been the subject of rigorous clinical study since the 1990s. The core of the investigative interest lies in the "DMT-Extended State" (DMTx) and the consistency of reports regarding an "11-dimensional" or "hyperspatial" architecture that remains topologically invariant across diverse, unrelated test subjects.
The stakes of this research involve the potential validation of the "Brain-as-Receiver" filter theory versus the "Endogenous Hallucinogen" model. Current investigations by the University of Greenwich and Imperial College London utilize Target-Controlled Infusion (TCI) to keep subjects in the DMT space for extended durations. The strongest documented findings indicate that subjects report a stable, navigable environment that behaves with its own internal physics, leading to a live debate between neurobiologists, who view these sightings as neural-mapping errors, and mathematical physicists, who suggest DMT may allow the human nervous system to interface with extra-dimensional manifolds theorized in M-Theory.
Key Claims
- Dimensional Invariance: Proponents claim that the DMT experience is not a random hallucination but a "consistent geography" or a "Level II state" where the geometry transitions from 3D/4D Euclidean space to 11-dimensional Calabi-Yau manifolds.
- The "Extended State" Hypothesis: Research teams claim that through intravenous TCI, the "DMT space" can be stabilized for 30–60 minutes, allowing for cartographic mapping of these dimensions.
- Non-Human Intelligence (NHI) Interaction: A central claim is the recurring presence of "Machine Elves" or "Tykes" who appear to inhabit these higher-dimensional planes and perform "technological demonstrations."
- Endogenous Function: Some researchers claim the pineal gland or the lungs synthesize DMT in quantities sufficient to trigger these states during birth, death, or REM sleep (first popularized by Dr. Rick Strassman).
- Information Transfer: It is claimed that subjects can retrieve novel mathematical or linguistic information from these 11th-dimension "vantage points" that they did not possess prior to the experience.
- Ontological Shock: The assertion that the DMT state is "more real than real," a phenomenon where subjects rate the experience as having higher "veridicality" than waking reality on standardized psychometric scales.
Evidence & Documentation
- Strassman, R. (1990-1995) UNM Clinical Trials: The first declassified/approved FDA study of a Schedule I hallucinogen in the US since the 1970s. Documented over 400 doses in 60 volunteers, establishing the "entity contact" protocol.
Imperial College London (2019) EEG/fMRI Study: Published in Scientific Reports*, this study mapped the transition from alpha to theta/delta waves, showing a massive increase in global functional connectivity, mirroring a "higher state of entropy."
Gallimore, A. & Strassman, R. (2016) "A Model for the Application of Target-Controlled Intravenous Infusion of DMT": This paper, published in Frontiers in Pharmacology*, provides the mathematical framework for the DMTx protocol to extend the "hyperspace" experience.
The Johns Hopkins Entity Survey (2020): Published in the Journal of Psychopharmacology*, this survey of 2,561 individuals documented that 80% of respondents reported communication with an NHI during the DMT state.
Timmermann, C., et al. (2023) "Neural correlates of the DMT experience": Published in PNAS*, this study used simultaneous fMRI-EEG to show that DMT creates a "breakdown of hierarchy" in the brain, allowing for the perception of complex, high-dimensional visual information.
- The DMTx Mapping Project (2022–Present): Ongoing data from the Center for Psychedelic Research at Imperial College using the "DMTx" protocol to attempt "inter-dimensional cartography."
- National Institute of Health (NIH) - RePORTER Project 1R01MH119536-01: Evidence of federal funding for studies into the molecular mechanisms of DMT and its interaction with the Sigma-1 receptor.
Key Actors & Organizations
Dr. Rick Strassman: Associate Professor of Psychiatry at the University of New Mexico School of Medicine; principal investigator of the 1990s DMT trials and author of DMT: The Spirit Molecule*.
- Dr. Andrew Gallimore: Computational neurobiologist and pharmacologist; developed the pharmacological models for the DMTx (Extended State) technology used to navigate the 11th dimension.
- Dr. Robin Carhart-Harris: Former head of the Centre for Psychedelic Research at Imperial College London; primary architect of the fMRI mapping of DMT states.
- Terence McKenna: Ethnobotanist (deceased); popularized the "Machine Elf" and "Hyperspace" theories in the 1980s and 1990s, serving as the primary qualitative source for researchers.
- The Cottonwood Research Foundation: A non-profit research organization (founded by Strassman et al.) dedicated to the study of the nature of consciousness and endogenous DMT.
- Dr. David Nichols: Medicinal chemist and pharmacologist at Purdue University; synthesized the high-purity DMT used in early clinical trials and researched its binding affinity for the 5-HT2A receptor.
Graham Hancock: Investigative journalist whose 2005 book Supernatural* cross-referenced DMT "entity" sightings with Paleolithic cave art and modern UFO abduction reports.
Counter-Evidence & Fact-Checks
The Pineal Gland Debunk: While Dr. Strassman hypothesized the pineal gland as the source of DMT, a 2013 study (Barker et al.) found DMT in the pineal glands of rats, but no study has conclusively proven the human pineal gland can produce the concentration* required to trigger a breakthrough.
- Hypnagogic Hallucination Model: Skeptics argue that DMT "entities" are simply archetypal manifestations of the brain's facial recognition hardware (the fusiform face area) misfiring under serotonergic stress.
- The "Phosphene" Rebuttal: Mainstream visual science suggests that the "high-dimensional geometry" is merely the subjective perception of the physical structure of the retina and the visual cortex (Turing patterns).
- Cultural Priming: Skeptics point out that many modern DMT reports are influenced by McKenna’s lectures, though this is countered by Strassman’s 1990 subjects who had never heard of McKenna but reported identical "beings."
Timeline
- 1931-01-01 — First synthesis of DMT by Canadian chemist Richard Manske.
- 1956-06-01 — Dr. Stephen Szara demonstrates the hallucinogenic properties of DMT in humans via intramuscular injection.
- 1970-10-27 — DMT is classified as a Schedule I substance under the Controlled Substances Act.
- 1990-12-01 — Dr. Rick Strassman begins the first FDA-approved human DMT trials at the University of New Mexico.
2000-12-01 — Strassman publishes DMT: The Spirit Molecule*, bringing the "entity contact" data to the public.
- 2016-07-14 — Gallimore and Strassman publish the "DMTx" paper, proposing the use of anesthetic infusion pumps to stay in "hyperspace."
- 2019-11-19 — Imperial College London publishes the first comprehensive EEG mapping of the DMT state.
- 2022-07-01 — The first "DMTx" clinical trials begin at the University of Greenwich, successfully keeping subjects in the state for 45 minutes.
2023-03-20 — The PNAS* study on DMT reveals the "unfolding" of the brain’s hierarchy, providing a neurological basis for "extra-dimensional" perception.
Money & Operational Flow
- Private Philanthropy: Initial research in the 1990s and early 2000s was largely funded by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Heffter Research Institute.
- The COMPASS Pathways Connection: A major for-profit player in the psychedelic space, COMPASS (CMPS) has invested millions in synthetic tryptamine patents and delivery systems, though primarily focused on Psilocybin.
- DMTx Funding: The current extended-state trials are funded by a mix of university grants and private donors, including the "Beckley Foundation," which funds research into "the bridge between neuroscience and the nature of consciousness."
- Operational Mechanics: DMTx utilizes an Alaris infusion pump calibrated with a two-compartment pharmacokinetic model. The "loading dose" clears the threshold, followed by a "maintenance infusion" to keep plasma levels constant, effectively freezing the subject in the peak of the 11-dimensional visual phase.
Open Questions & Unresolved Threads
- The Invariance Problem: Why do subjects from disparate cultures (e.g., a New York atheist vs. a South American tribesman) describe the same high-dimensional "gatekeepers" and geometric "nurseries"?
- Physical Trace Theory: Can a DMT subject retrieve a specific prime number or verifiable physical fact from the "11th dimension" that they could not have known? (Current protocols are testing this).
- Endogenous Release Triggers: What is the precise enzymatic trigger for endogenous DMT release in humans, and does it coincide with the "Near-Death Experience" (NDE)?
- Mathematics of the Geometry: Are the fractal patterns seen under DMT mathematically identical to the Calabi-Yau manifolds predicted by String Theory, or is it a visual approximation?
Connected Topics
- M-Theory (String Theory): The mathematical framework suggesting that the universe consists of 11 dimensions, many of which are "curled up" or "compactified."
- The Sigma-1 Receptor: A unique chaperone protein that DMT binds to, which is linked to cellular stress and neuroprotection, differing from other psychedelics.
- Ayahuasca: The Amazonian brew containing DMT and an MAO inhibitor (Harmine), which allows for a 4–6 hour DMT experience through oral ingestion.
- UFO/NHI "Interdimensional" Hypothesis: Theories by Jacques Vallée suggesting that "aliens" may be extra-dimensional entities rather than extraterrestrial, utilizing a similar "frequency" to the DMT state.
Credibility Assessment: INDEPENDENT-INVESTIGATED
While the physiological effects of DMT are DECLASSIFIED and MAINSTREAM-REPORTED, the specific "11th dimension" claims remain in the realm of INDEPENDENT-INVESTIGATED. The neurological data proves that DMT alters the brain's spatial-processing hierarchy, but the ontological reality of a "separate dimension" is currently a hypothesis being tested via the DMTx cartography protocols.
Sources
- Strassman, R. (2001). DMT: The Spirit Molecule. Park Street Press. [Official Study Archive]
- Gallimore, A. (2019). Alien Information Theory: Psychedelic Drug Technologies and the Cosmic Game. Strange Attractor Press.
- Timmermann, C., et al. (2019). "Neural correlates of the DMT experience assessed with EEG." Scientific Reports. https://www.nature.com/articles/s41598-019-51974-4
- Davis, A. K., et al. (2020). "Survey of entity encounter experiences occasioned by DMT." Journal of Psychopharmacology. https://journals.sagepub.com/doi/10.1177/0269881120916143
- Frontiers in Pharmacology (2016). "A Model for the Application of Target-Controlled Intravenous Infusion of N,N-Dimethyltryptamine." https://www.frontiersin.org/articles/10.3389/fphar.2016.00211/full
- PNAS (2023). "Human brain effects of DMT assessed via fMRI-EEG." https://www.pnas.org/doi/10.1073/pnas.2218949120
- The Beckley Foundation. "DMT Research Programme." https://www.beckleyfoundation.org/dmt-research-programme/
- Barker, S. A., et al. (2013). "LC/MS/MS analysis of endogenous DMT in rat pineal gland." Biomedical Chromatography.
EXPANSION PASS — Additional Depth
Lesser-Known Actors
- Stephen Szára: Hungarian chemist and psychiatrist. After being denied Mescaline by Sandoz, he synthesized DMT in 1956 and performed the first human trials in Budapest, discovering the substance was only active via injection, not ingestion.
- Amanda Feilding: Countess of Wemyss and March; founder of the Beckley Foundation. The "hidden hand" behind modern DMT funding, she has coordinated high-level scientific meetings since the 1990s to move DMT from counter-culture to clinical legitimacy.
- Jace Callaway: Pharmaceutical chemist who first identified the "Hoasca Project" mechanism. He was instrumental in identifying the role of endogenous Beta-carbolines in potentiating DMT and theorized the existence of "Endopsychotogens."
- Ede Frecska: Chief of Psychiatry at the National Institute of Psychiatry and Neurology in Budapest. He has focused on DMT’s role as a "signaling molecule" at the Sigma-1 receptor, arguing it protects cells during oxidative stress and hypoxia.
- Luis Eduardo Luna: Anthropologist and director of Wasiwaska. He acted as the primary bridge between the "Vegetalista" traditions of the Amazon and Western researchers, specifically introducing the concept of "icaros" as navigational tools for the DMT state.
- Dave King: Founder of the Breaking Convention conference. A key fixer in the UK psychedelic research scene who helped facilitate the networking required for the Imperial College DMT studies.
- Dr. Steven Barker: Former Director of the Louisiana State University Agricultural Center’s State Evidence Laboratory. He developed the hyper-sensitive mass spectrometry methods used to detect picogram levels of DMT in mammalian tissues.
Document Deep-Cuts
- DEA Controlled Substance Code Number (CSCN): 7435. The internal administrative tracking code for N,N-Dimethyltryptamine.
- FDA IND (Investigational New Drug) #33,852: The original regulatory filing number for Rick Strassman’s UNM trials (1990).
- United Nations Convention on Psychotropic Substances (1971), Schedule I: The international treaty document that mandated global prohibition, despite DMT occurring naturally in thousands of species.
- US Patent #11,541,036: "Methods and compositions for treating psychological disorders with DMT." Held by GH Research (Ireland), filed in 2022, detailing specific aerosolized delivery mechanics for rapid onset.
- NIH Grant #R01DA044234: "Molecular Mechanisms of Psychedelic Action." Federal funding allocated to investigating how DMT-like molecules reorganize cortical architecture.
- Nuremberg Code Compliance Memo (UNM 1990-04-12): Internal ethics board document addressing the "ontological risk" to subjects participating in high-dose DMT research.
Wider Timeline
1954-05-14 — Fish, Johnson, and Horning identify DMT as the primary active alkaloid in Anadenanthera peregrina* (Yopo) seeds used by indigenous Orinoco tribes.
- 1965-02-12 — First reported isolation of DMT from human blood and urine by German researchers, sparking the "Transmethylation Hypothesis" of schizophrenia.
1976-11-03 — Publication of "The Psychopharmacology of DMT" in Psychopharmacology Communications*, establishing the 30-minute biological half-life.
- 1988-09-20 — The "Palenque Entheogen Conference" where the underground blueprint for modern DMT theory was first synthesized by McKenna and Bigwood.
2005-06-15 — The Supreme Court of the United States hears Gonzales v. O Centro Espírita Beneficente União do Vegetal*, a landmark case regarding the religious use of DMT-containing tea.
2011-02-28 — Release of the documentary DMT: The Spirit Molecule*, which caused a 400% spike in "DMT" search queries and a subsequent surge in underground manufacturing.
- 2014-08-11 — Researchers at the University of Michigan document a surge of neurochemicals, including potential DMT-precursors, in the brains of rats during cardiac arrest.
- 2021-12-14 — Small Pharma (UK) announces the world's first Phase I/IIa clinical trial for "SPL026" (IV DMT) for the treatment of Major Depressive Disorder.
2024-01-10 — Publication of "DMT and the Brain's Predictive Coding Hierarchy" in Nature Communications*, suggesting DMT disables the "Prior Belief" filter of the brain.
Money & Operational Mechanics — Deeper
- The "GH Research" Capitalization: GH Research PLC (Nasdaq: GHRS) went public with a valuation exceeding $800 million, specifically to develop DMT-based therapies, indicating massive institutional "long" positions on DMT technology.
- Synthetic Sourcing: High-purity DMT for research is typically synthesized via the "Speeter-Anthony Procedure," utilizing oxalyl chloride and indole. A single gram of GMP-grade (Good Manufacturing Practice) DMT can cost research institutions upwards of $5,000–$10,000 due to regulatory compliance.
- The "Pharmahuasca" Loophole: Use of "MAOIs" (Monoamine Oxidase Inhibitors) such as Harmine/Harmaline to bypass the digestive breakdown of DMT. Operational cost for underground labs is approximately $0.50 per dose, creating a massive price-to-value disparity compared to clinical DMT.
- Vaporization Mechanics: The "E-mesh" technology. A specialized vaping apparatus using stainless steel mesh sheets to instantaneously sublimate DMT at exactly 160°C, ensuring the "one-hit breakthrough" that traditional glass pipes rarely achieve.
- The "Beckley/Imperial" Partnership: A complex co-funding model where private donors (The Psychedelic Science Funders Collaborative) bypass government restriction by funding UK-based entities to perform research the US NIH is politically hesitant to lead.
Suppressed or Retracted Material
- The 1970s "Schizophrenia-DMT" Retractions: Multiple studies suggesting DMT was the "cause" of madness were retracted or sidelined when it was discovered that healthy controls also produced endogenous DMT.
- The "60 Minutes" Segment (Unaired/Suppressed): Reports of an early 1990s TV segment on Strassman’s research that was allegedly spiked due to concerns it would "promote drug use" despite featuring clinical data.
- The Case of "Patient 4" (Strassman Trials): Specific session notes involving a terrifying "alien abduction" experience that were partially redacted from early public lectures to avoid sounding too "fringe" for the medical community.
Customs Seizure "Grey Area": Frequent "Administrative Seizures" by the DEA of Mimosa hostilis* bark shipments. These are often not prosecuted but the material is destroyed, acting as a "soft suppression" of DMT precursor availability.
Open Threads — Specific FOIA / Investigative Targets
- FDA/CDER (Center for Drug Evaluation and Research): Request all Adverse Event Reporting System (FAERS) data for "Dimethyltryptamine" from 1990 to present, specifically focusing on "Psychological/Ontological Distress."
- DEA Office of Diversion Control: FOIA request for the "Aggregate Production Quota" (APQ) for DMT (Drug Code 7435) for the years 2010–2024 to see how much production has been authorized for "industrial/research" use.
- National Institute on Drug Abuse (NIDA): Request records regarding "Project 2901," an internal review of endogenous hallucinogens and their link to spontaneous mystical experiences.
- Department of Defense (DoD): FOIA request for any "Human Performance Wing" research into "Rapid State Change" or "Cognitive Decoupling" utilizing tryptamines (Date range: 2015–present).
Customs and Border Protection (CBP): Request "Seizure Logs" for Mimosa hostilis and Psychotria viridis* to map the geographical flow of "precursor" material into the US.
- University of New Mexico (UNM) Internal Review Board: Request the original "Risk Management" memos for the 1990 DMT trials to see what specific "spiritual" or "mental" risks the university was most afraid of.
Adjacent Files in The Vault
- The 5-MeO-DMT Protocol: Investigation into "The Toad" (Incilius alvarius), a DMT analog that produces a "white-out" void experience rather than the "entity-dense" geometry of N,N-DMT.
- Project MKUltra Subproject 58: The early CIA search for South American "magic plants" and their potential for interrogative "mind-shattering" applications.
- The Stargate Project (Remote Viewing): Overlap in descriptions between "Target Sites" in remote viewing sessions and the "Navigable Hyperspace" of DMT.
- Near-Death Experience (NDE) Meta-Analysis: Cross-reference of the "Life Review" and "Tunnel of Light" phenomena with the DMT "Transit" phase.
Additional Sources
- Szára, S. (1956). "Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism." Experientia.
- Callaway, J. C. (1988). "A proposed mechanism for the visions of Ayahuasca." Journal of Ethnopharmacology.
- Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press. (The definitive chemical encyclopedia of tryptamines).
- Luna, L. E. (1986). Vegetalismo: Shamanism Among the Mestizo Population of the Peruvian Amazon. Stockholm: Almqvist & Wiksell International.
- Barker, S. A. (2018). "N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function." Frontiers in Neuroscience.
- Cozzi, N. V., et al. (2009). "Dimethyltryptamine and other hallucinogenic tryptamines can be substrates for the human platelet serotonin transporter." Journal of Neural Transmission.
- Winkelman, M. (2010). Shamanism: A Biopsychosocial Paradigm of Consciousness and Healing. ABC-CLIO.
- Nataraj, J., et al. (2020). "DMT as a possible endogenous σ-1 receptor ligand." Journal of Receptors and Signal Transduction.
- Uthaug, M. V., et al. (2020). "A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life." Psychopharmacology.
- Frecska, E., et al. (2013). "The therapeutic potentials of ayahuasca: possible role against various diseases of 21st century civilization." Frontiers in Pharmacology.
Names this file mentions repeatedly but never made an explicit subject. Click any chips to select multiple, then hit Investigate as Connection to spin them up on Connect-the-Dots together with the file's existing subjects.
For every named entity in this file, each cell shows how many other files in that category mention it — files of all kinds counted together. Click a hot cell to jump to a matching file (or, if the entity has never been investigated, into a fresh Deep Dive pre-filled with it). Tick row checkboxes then hit Investigate as Connection to spin up multiple entities on Connect-the-Dots.
| ☐ Entity | big tech surveillance | corporate finance | elections integrity | great awakening | health pharma | historical declassified | mind control psyops | political assassinations | trafficking networks | uap disclosure | war false flags | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Burn 100 coins to mint a real collectible Vault Card from this file. The FIRST mint of this artifact rolls the rarity once and locks it forever — every future mint of the same file gets an identical-looking card, differing only by edition number.
Rarity odds: RARE 50% · MYTHIC 35% · CLASSIFIED 15%. Card art is generated by Gemini Nano Banana in the brutalist Vault style and lives forever on the public profile of every minter.
If you read this, read these
Humans emerging from water consciousness compared to other aliens
DOSSIER: Extraterrestrial Interest in Water-Based Human Consciousness Executive Summary This proposition posits that extraterrestrial entities may specifically target humans for study or contac
Cern
Executive Summary The European Organization for Nuclear Research (CERN), established in 1954, operates the world’s largest and most powerful particle accelerator, the Large Hadron Collider (LHC).
cloud seeding
CLOUD SEEDING OPERATIONS DOSSIER Executive Summary Cloud seeding is the deliberate introduction of substances (typically silver iodide, dry ice, or salt) into clouds to modify precipitation out
The Federal Reserve
The Federal Reserve: Institutional Architecture & Governance Disputes Executive Summary The Federal Reserve System, established by the Federal Reserve Act of 1913, is the central banking system
Spoon theory
SPOON THEORY: Investigative Dossier Executive Summary Spoon theory is a cognitive framework for describing energy limitations in chronic illness and disability, using "spoons" as metaphorical u
Kandahar Giant
The Kandahar Giant: Investigative Dossier Executive Summary The "Kandahar Giant" refers to an unverified claim that a multinational military unit in Kandahar, Afghanistan allegedly encountered